Scleroderma is a progressive autoimmune disease affecting multiple organs. Fibrosis, the hallmark of scleroderma, represents transformation of self-limited wound healing into a deregulated self-sustaining process. The factors responsible for maintaining persistent fibroblast activation in scleroderma and other conditions with chronic fibrosis are not well understood. Toll-like receptor 4 (TLR4) and its damage-associated endogenous ligands are implicated in immune and fibrotic responses. We now show that fibronectin extra domain A (Fn EDA ) is an endogenous TLR4 ligand markedly elevated in the circulation and lesional skin biopsies from patients with scleroderma, as well as in mice with experimentally induced cutaneous fibrosis. Synthesis of Fn EDA was preferentially stimulated by transforming growth factor-b in normal fibroblasts and was constitutively up-regulated in scleroderma fibroblasts. Exogenous Fn EDA was a potent stimulus for collagen production, myofibroblast differentiation, and wound healing in vitro and increased the mechanical stiffness of human organotypic skin equivalents. Each of these profibrotic Fn EDA responses was abrogated by genetic, RNA interference, or pharmacological disruption of TLR4 signaling. Moreover, either genetic loss of Fn EDA or TLR4 blockade using a small molecule mitigated experimentally induced cutaneous fibrosis in mice. These observations implicate the Fn EDA -TLR4 axis in cutaneous fibrosis and suggest a paradigm in which aberrant Fn EDA accumulation in the fibrotic milieu drives sustained fibroblast activation via TLR4. This model explains how a damage-associated endogenous TLR4 ligand might contribute to converting self-limited tissue repair responses into intractable fibrogenesis in chronic conditions such as scleroderma. Disrupting sustained TLR4 signaling therefore represents a potential strategy for the treatment of fibrosis in scleroderma.
INTRODUCTION
Scleroderma is a chronic disease of unknown etiology and substantial mortality characterized by autoimmunity, inflammation, and intractable tissue fibrosis. Because it has no validated biomarkers or effective disease-modifying therapies, scleroderma represents a major unmet medical need (1) . The early inflammatory stage of scleroderma is often followed by tissue deposition of collagen-rich scar that disrupts the normal architecture and leads to dysfunction and eventual failure of the skin, lungs, and other organs (2) . Although transforming growth factor-b (TGF-b) is recognized as an important trigger for fibroblast activation (3), the factors responsible for maintaining chronic fibrosis remain incompletely understood (4) . As the primary extracellular matrix (ECM)-producing stromal cells, myofibroblasts serve as the key effectors of fibrogenesis (5) . Multiple extracellular cues including soluble cytokines and chemokines, reactive oxygen species, and biomechanical signals induce stimulation of collagen and ECM molecule synthesis, and acquisition of a contractile myofibroblast phenotype. Ultimately, the establishment of self-amplifying feed-forward loops in lesional tissues may account for the failure to restrain fibroblast activation, and a fundamental unanswered question in scleroderma is the nature of the autocrine and paracrine signaling pathways that underlie these loops (6) .
Toll-like receptors (TLR) recognize both microbial pathogen-associated molecular patterns and nonmicrobial endogenous ligands (7) . Endogenous TLR4 ligands display molecular patterns that are normally inaccessible to the immune system but are released passively into the extracellular space upon cell injury or necrosis, or activation after chronic injury. Matrix molecules such as biglycan, tenascin C, and hyaluronic acid are up-regulated or undergo oxidation or fragmentation upon tissue injury and serve as potential endogenous TLR4 ligands (8) . Because they are normally inert and are recognized by TLRs only upon injury, these "damage-associated molecular patterns" (DAMPs) serve as danger signals that enable the innate immune system to sense and respond to sterile tissue damage (9, 10) . Accumulating evidence implicates DAMP-triggered aberrant TLR signaling in chronic inflammatory and fibrotic disorders, as well as in mouse models of disease (11) (12) (13) (14) . Skin and lung biopsies from patients with scleroderma show elevated levels of endogenous TLR4 ligands and constitutive TLR4 signaling, but the signals responsible for TLR4 activation and their role in pathogenesis remain unknown (15, 16) .
Fibronectins are high-molecular weight modular glycoproteins that circulate in soluble form in plasma or accumulate in tissue as insoluble ECM components (17) . Because of alternate splicing of the fibronectin gene, cellular fibronectin contains extra domains A (EDA) and B (EDB), which are excluded from plasma fibronectin (18) . The EDA-containing fibronectin variant (Fn EDA ) fulfills dual function as both structural ECM scaffold and signaling molecule regulating adhesive, proliferative, and migratory cellular responses, and plays an important role in myofibroblast differentiation and wound healing (19, 20) . Although there is little Fn EDA expression in adult tissues, marked transient up-regulation is seen during normal wound healing and tissue repair (21) (22) (23) (24) . Cellular responses elicited by Fn EDA are mediated via both surface integrins and TLR4 (24) (25) (26) (27) (28) .
The present studies were undertaken to investigate the expression and regulation of Fn EDA in scleroderma, and its role and mechanism of action in fibrosis. The results reveal significant elevation of Fn EDA in the serum and skin from patients with scleroderma, as well as in lesional tissues from mice with cutaneous fibrosis. Exogenous Fn EDA had potent effects on collagen gene expression, myofibroblast differentiation and in vitro wound healing, and increased matrix stiffness and collagen cross-linking in human skin equivalents. These ex vivo fibrotic responses were abolished by either genetic or pharmacological disruption of fibroblast TLR4 signaling. Moreover, mice lacking Fn EDA or treated with a TLR4 inhibitor showed attenuation of inducible cutaneous fibrosis. Together, our results indicate that Fn EDA is aberrantly expressed in patients with scleroderma, induces fibrotic response via TLR4, and is required for maximal cutaneous fibrogenesis in the mouse. On the basis of these findings, we propose the following paradigm for pathological fibrogenesis: Injury triggers increased production and persistent extracellular accumulation of Fn EDA , which in turn induces TLR4-dependent fibrotic responses including Fn EDA synthesis. The ensuing positive feedback loop is likely to contribute to the persistence and progression of fibrosis in scleroderma. The results from these studies might inform the development of therapeutic approaches to control fibrosis in scleroderma.
RESULTS

Elevated Fn
EDA levels in scleroderma To assess Fn EDA expression in scleroderma, we pursued two approaches. First, serum levels were determined in 48 patients with diffuse cutaneous scleroderma and 16 healthy adults recruited from a single institution. The clinical characteristics of the subjects are shown in Table 1 . Ninety-five percent of the scleroderma patients were women, and 18 had early-stage (<2 years) disease. A fivefold increase in serum Fn EDA levels was seen in scleroderma patients compared to control subjects (mean, 20.2 ± 1.6 mg/ml versus 4.5 ± 0.8 mg/ml; P < 0.0001) (Fig. 1A) . The 95% confidence interval in control subjects was <6.3 mg/ml; 94% of scleroderma patients had elevated Fn EDA levels. No significant correlation was found between Fn EDA levels and disease duration, modified Rodnan skin score (mRSS), forced vital capacity (FVC) or diffusing capacity for carbon monoxide (DLco), or change in mRSS during a 6-month follow-up period (tables S1 and S2).
Next, tissue levels of Fn EDA mRNA and protein were examined. RNA was isolated from biopsies of lesional skin from 20 scleroderma patients or forearms of 8 healthy volunteers (Table 2) . Real-time quantitative polymerase chain reaction (qPCR) results showed a nearly threefold increase (P = 0.0002) in Fn EDA mRNA in scleroderma biopsies compared to matched controls (Fig. 1B) . Immunofluorescence showed that healthy control skin (n = 6) had only barely detectable Fn EDA in the dermis, whereas scleroderma biopsies (n = 13) displayed a more than twofold increase (P = 0.016) (Fig. 1C and Table 3 ). Together, these results indicate that the Fn EDA splice variant is selectively elevated in both serum and lesional skin biopsies from patients with scleroderma.
Preferential stimulation of Fn
EDA in TGF-b-treated normal fibroblasts The elevated expression of Fn EDA in scleroderma patients prompted us to investigate the mechanisms underlying its regulation. For this purpose, quiescent foreskin fibroblasts were incubated with TGF-b for up to 48 hours, and RNA and protein were analyzed by real-time qPCR and immunoblotting. The results showed that TGF-b induced a dose-dependent increase in levels of both Fn EDA mRNA (maximal >30-fold) and protein (>9-fold) in these fibroblasts (Fig. 1D ). In contrast to the marked up-regulation of the EDA splice variant, fibronectin showed only a modest (about threefold) increase in response to TGF-b. To identify signaling pathways underlying TGF-b stimulation of Fn EDA , fibroblasts were pretreated with the selective activin receptorlike kinase 5 (ALK5) inhibitor SB431542 or the mitogen-activated protein kinase kinase (MEK1/2) inhibitor U0126 for 30 min before the addition of TGF-b. The stimulatory effects of TGF-b on Fn EDA were completely abolished in the presence of SB431542, whereas U0126 had no effect, indicating a primary role for the canonical Smad pathway (Fig. 1E) .
Attenuated dermal fibrosis in Fn
EDA -null mice To explore the potential role of Fn EDA in tissue remodeling in vivo, mice with homozygous exclusion of the EDA were studied (21) . Fn EDA -null mice were viable, developed normally, and showed no overt phenotype. Cutaneous fibrosis was induced by daily subcutaneous injections of bleomycin (15) . Mice were sacrificed at day 24, and lesional skin was harvested for analysis. A twofold increase in dermal thickness (P < 0.0001) and collagen accumulation (P = 0.02) was evident in wild-type C57BL/6 mice treated with bleomycin ( Fig. 2A) . Similarly treated Fn EDA -null mice showed significantly reduced dermal thickness (P < 0.001) and collagen (P = 0.015). Immunofluorescence demonstrated a marked increase in Fn EDA accumulation in the dermis in wild-type mice injected with bleomycin, whereas no Fn EDA could be detected in Fn EDA -null mice, as expected ( fig. S1, A and B) . Real-time qPCR results showed that bleomycin-induced up-regulation of collagen and a smooth muscle actin (aSMA) mRNA in the fibrotic skin was significantly attenuated, and the proportion of aSMA-positive fibroblasts markedly decreased, in Fn EDA -null mice (Fig. 2, B and C) . Moreover, the increase in the number of phospho-Smad2-positive cells in the fibrotic dermis was significantly attenuated in Fn EDA -null mice ( fig. S2, A and B) . Multiple ECM components are implicated in the progression of organ fibrosis (29) . Elastin, the main component of elastic fibers, provides structural integrity and is responsible for the elastic properties of the skin and other organs (30, 31) . Previous studies have implicated aberrant elastin deposition and organization in scleroderma, as well as murine models of fibrosis (32) (33) (34) -null mice in parallel by subcutaneous injections of adenovirus expressing constitutively active TGF-b1 (AdTGF-b1). Mice were sacrificed 28 days after the second subcutaneous injection, and lesional skin was analyzed. In contrast to wild-type mice that showed a~50% increase in dermal thickness (P = 0.02), in Fn EDA -null mice, AdTGF-b1 elicited only a 15% increase (P = 0.20) (Fig. 2D) . Moreover, collagen fiber deposition in the lesional dermis was notably attenuated. Results from these complementary animal models together indicate that Fn EDA plays a fundamental role in the development of experimentally induced cutaneous fibrosis. EDA resulted in substantially enhanced aSMA expression and stress fiber incorporation (Fig. 3B) . In stark contrast to Fn EDA , fibronectin had no effect on collagen and aSMA expression under similar experimental conditions ( fig. S3E ). Furthermore, preincubation of the cultures with a neutralizing antibody specific for the EDA domain abrogated the profibrotic effects, indicating the essential role of the EDA domain in triggering these responses ( fig. S3E) .
Cell migration and matrix contraction are fibroblast responses required for effective wound healing, and their deregulation is implicated in pathological fibrogenesis (35, 36) . To evaluate the effect of Fn EDA on in vitro wound healing, we used a pipette tip to create a linear scratch in confluent fibroblast monolayers plated on dishes coated with or without Fn EDA (10 mg/ml), and cell migration into the wounded area was monitored for up to 48 hours. As shown in Fig. 3C (left panel), fibroblasts grown on Fn EDA -coated plastic showed significantly accelerated migration compared to fibroblasts on uncoated plastic. Moreover, fibroblast contractility in collagen gels was enhanced when Fn EDA (10 mg/ml) was incorporated in the gels (Fig. 3C, right panel) .
Substrate stiffness has profound influence on fibrogenesis by modulating fibroblast morphology, migration, differentiation, and survival (37) . Plastic dishes traditionally used for cell culture studies present an excessively rigid substrate with stiffness approaching 2 GPa, potentially EDA serum levels in scleroderma patients (n = 48) and healthy adults (n = 16) were determined by enzyme-linked immunosorbent assay (ELISA). Each data point is the mean ± SD of triplicate determinations from a single subject. *P < 0.0001, Mann-Whitney U test. (B) RNA isolated from skin biopsies from scleroderma patients (n = 20) and healthy adults (n = 8) was analyzed by real-time qPCR. Results, expressed relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are the means ± SD of duplicate determinations. *P = 0.0002, Mann-Whitney U test. (C) Immunofluorescence analysis. Skin biopsies from scleroderma patients (n = 13) and healthy controls (n = 6) in parallel were immunostained with antibodies to Fn EDA and examined by immunofluorescence confocal microscopy. Upper panels: Representative images. Scale bar, 25 mm. Lower panels: 3D plots of fluorescence intensity (see Table 3 ). P = 0.0159, Mann-Whitney U test. (D and E) Confluent human skin fibroblasts were incubated for 24 hours with TGF-b (1 and 10 ng/ml) alone (D) or in the presence or absence of SB431542 or U0126 (E). (D) Upper panel: Levels of mRNA were determined by real-time quantitative PCR. Results, normalized with GAPDH, are means ± SD of triplicate determinations. *P < 0.0001, one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test. Lower panel: Whole-cell lysates were subjected to Western analysis. Representative immunoblots. confounding the interpretation of the results (38) . To dissociate the effect of Fn EDA on fibroblasts from that of mechanical forces imparted by the stiff substrate, we took an alternate experimental approach using human fibroblasts embedded in three-dimensional (3D) organotypic skin raft cultures that spontaneously organize a "dermal compartment" with mechanical stiffness approximating that of normal dermis (39) . Normal fibroblasts were embedded in skin rafts made with or without Fn EDA for 14 days, followed by harvesting and analysis of the dermal compartment. Inclusion of Fn EDA in the rafts was associated with a significant increase in deposition of cross-linked "mature" collagen ( Fig.  3D ). Western analysis confirmed increased collagen (1.8-fold) and aSMA (~1.7-fold) accumulation in the dermal compartment when Fn EDA was included (Fig. 3E ). We next examined the effect of Fn EDA on substrate stiffness in the 3D skin equivalents. Organotypic human skin equivalents constructed using collagen only elaborated a matrix that had physiological stiffness (~600 Pa), whereas incorporation of Fn EDA into the rafts resulted in a concentration-dependent increase in stiffness of the dermal compartment (Fig. 3F ). Stiff substrates directly promote fibrogenesis by eliciting fibrotic responses such as type I collagen production in explanted fibroblasts (37, 39) . These complementary ex vivo models together demonstrate that Fn EDA exerts potent profibrotic effect on fibroblasts in both 2D monolayers and 3D skin organotypic human skin equivalents. elicited a range of classic inflammatory TLR4 responses, including marked stimulation of interleukin-6 (IL-6) secretion and NF-kB-luc activity (Fig. 4B and fig. S3 ). The stimulatory effect of Fn EDA was attenuated when cultures were pretreated with neutralizing antibodies specific for the EDA domain (Fig. 4B) (Fig. 4C) . Second, selective small interfering RNA (siRNA) knockdown of TLR4 was accompanied by substantially reduced Fn EDA stimulation of collagen gene expression and myofibroblast differentiation (Fig. 4D) . To further confirm the essential role of TLR4 in the Fn EDA response, we pursued a genetic loss-of-function approach using TLR4-mutant C3H/HeJ mice that harbor a TLR4 missense mutation, resulting in LPS hyporesponsiveness (41) . Primary skin fibroblasts explanted from C3H/HeJ mice and wild-type C3H/HeOuJ mice were grown to confluence in parallel and incubated with Fn EDA for 72 hours. Western analysis showed that in contrast to wild-type control fibroblasts, in TLR4-mutant fibroblasts, Fn EDA failed to stimulate collagen synthesis (Fig. 4E) . Endotoxin contamination could not account for the stimulatory responses because preincubation of the cultures with polymyxin B did not abrogate the profibrotic effect of Fn EDA while effectively blocking LPS-induced cytokine as well as COL1A1 induction ( fig. S3D ). Moreover, stripping the Fn EDA preparation of LPS also failed to abrogate the stimulatory effects ( Fig. 4B and fig.  S3F ). Together, these pharmacological, RNA interference, and genetic approaches in combination unequivocally establish the sufficient and necessary role for TLR4 in mediating profibrotic responses elicited by Fn EDA .
To gain insight into the cellular mechanisms underlying the TLR4-dependent profibrotic Fn EDA responses, we examined the potential role of miR29, a microRNA of particular interest in light of its emerging role as master regulator of fibrotic responses implicated in scleroderma (15, 42, 43) . Incubation of normal fibroblasts with Fn EDA caused suppression of miR29a and miR29b, with a maximal~60% decrease at 72 hours ( fig. S4A ). The inhibitory response was abrogated by CLI-095, indicating its dependence on TLR4 ( fig. S4B ). Significantly, pre-miR29a abrogated the collagen stimulatory effect of Fn EDA , whereas miR29-specific antagomirs caused an increase in basal levels of COL1A1 mRNA and further enhanced the stimulatory response elicited by Fn EDA (fig. S4, C and D). These observations suggest that down-regulation of miR29 might be a mechanism underlying the profibrotic responses elicited by Fn EDA . †Immunofluorescence intensity. Each data point represents the mean intensity from four randomly selected high-power fields (hpfs) per sample. Mean immunofluorescence intensity in healthy control biopsies (n = 6) was 7.86 ± 4.62. P < 0.016 (healthy versus SSc) (Mann-Whitney U test).
Essential role of TLR4 for the development of cutaneous fibrosis Because our in vitro studies implicated Fn EDA -TLR4 signaling in fibrosis, we sought to evaluate the pathogenetic role of TLR4 in vivo using pharmacological TLR4 inhibition. Mice were given daily injections of subcutaneous bleomycin alone or concurrently with the TLR4 inhibitor CLI-095. There was no weight loss or other evidence of toxicity in mice treated with CLI-095. Lesional skin from mice treated with bleomycin showed a substantial increase in dermal thickness, accumulation of densely packed collagen bundles accompanied by loss of subcutaneous adipose, and marked necrosis of the subjacent skeletal muscle (Fig. 5A ). Mice treated with CLI-095 showed a significantly attenuated increase in dermal thickness (P < 0.001) and collagen deposition (24.0 to 11.4%, P = 0.034). Moreover, bleomycin-induced muscle necrosis was virtually absent. Real-time qPCR showed that CLI-095 treatment mitigated the up-regulation of COL1A1 and aSMA mRNA in the skin (Fig. 5B) . Additional experiments showed that TLR4 blockade reversed cutaneous fibrosis, with reduced dermal thickness, collagen accumulation (18.6 to 11.4%, P = 0.011), and collagen and aSMA mRNA expression, when mice were treated with CLI-095 starting at day 15 (Fig. 5, C and D) . These results demonstrate that pharmacological blockade of TLR4 using a well-tolerated small molecule both prevented and promoted regression of skin fibrosis, suggesting an essential role for TLR4 signaling in its development and persistence.
DISCUSSION
In scleroderma, the tightly regulated and self-limited repair process that normally leads to tissue regeneration in the skin and multiple organs is subverted, and the ensuing persistent fibroblast activation underlies pathological fibrosis (6, (11) (12) (13) (14) . We now show that an alternately spliced variant of fibronectin that is normally absent in adult tissue but up-regulated transiently upon injury was constitutively raised in both the serum and skin biopsies from patients with scleroderma, and its expression in normal fibroblasts was stimulated preferentially by TGF-b. Serving as a bona fide endogenous TLR4 ligand, Fn EDA elicited potent TLR-dependent fibrotic responses in monolayer fibroblast cultures and in organotypic human skin equivalents. Moreover, in mice, both genetic deletion of Fn EDA and pharmacologic blockade of TLR4 mitigated cutaneous fibrosis. Together, these observations identify an Fn pathway fundamental for maintaining sustained fibroblast activation implicated in scleroderma.
The Fn EDA splice variant is prominently expressed in embryogenesis but becomes undetectable in adults (17) . Physiologic tissue remodeling is associated with transient expression of Fn EDA , whereas cancer and chronic inflammation are associated with sustained elevation (44) (45) (46) (47) (48) (49) . Circulating levels of Fn EDA show marked increase after trauma, stroke, and ischemic heart disease (20) , and elevated circulating Fn EDA predicts liver fibrosis in patients with chronic hepatitis C patients (50 EDA or left untreated, and at confluence, scratch wounds were created. Fibroblast migration was determined by measuring gap width at 24 and 48 hours. Results are means ± SD of triplicate determinations at three randomly selected locations from triplicate determinations (at 24 hours, P = 0.0043; at 48 hours, P = 0.0450, Mann-Whitney U test). Right panel: Collagen gel contraction assays. Fibroblasts were seeded in type I collagen gels and were incubated in medium in the presence or absence of TGF-b and Fn EDA (10 mg/ml). At 6 and 24 hours, gel diameters were determined. Results, expressed as percentage of gel area compared to controls (time 0), are the means ± SD of triplicate determinations (at 24 hours: control versus TGF-b, P < 0.0001; control versus Fn EDA , P < 0.0001, one-way ANOVA followed by Bonferroni's multiple comparison test). (D) 3D human skin equivalents constructed without or with Fn EDA (10 mg/ml) were seeded with fibroblasts. After 18 days, rafts were stained with Picrosirius Red. Left panel: Representative images. Scale bars, 25 mm (a and b) or 10 mm (c and d). Right panel: Immunofluorescence intensity. Bars represent the means ± SD from six randomly selected hpf per raft from three independent raft experiments (P = 0.022, Mann-Whitney U test). (E) Total protein from dermal compartments was analyzed. Representative Western blot. Numbers below indicate relative band intensities (means from two independent experiments corrected for GAPDH in each lane). (F) Stiffness of the dermal compartment was determined as described in Materials and Methods. The results represent the means ± SD from three independent rafts (P < 0.0001, control versus Fn EDA low; P < 0. (60) . We now show that pretreatment with a TLR4 inhibitor prevented cutaneous fibrosis, collagen deposition, and myofibroblast accumulation and caused regression of established fibrosis when given therapeutically. MicroRNAs play fundamental roles in a variety of cellular responses. In particular, miR29 is thought to be important in controlling fibrogenesis and shows reduced expression in fibrotic conditions including scleroderma (61) (62) (63) (64) . In the present studies with normal fibroblasts, Fn EDA suppressed miR29a expression in a TLR4-dependent manner. Rescuing miR29a expression in Fn EDA -treated fibroblasts abrogated the stimulation of collagen gene expression, whereas suppressing miR29a using an antagomir enhanced the response, implicating miR29 as a possible mediator of the TLR4-driven profibrotic effects of Fn EDA (42, 65) . There are limitations to the current study. The cohort evaluated for serum Fn EDA levels was relatively small, precluding firm conclusions regarding the utility of serum Fn EDA as a biomarker in scleroderma or as a marker of organ involvement or disease activity. It should be informative to compare serum Fn EDA levels in chronic autoimmune and fibrotic diseases. Although our results demonstrate marked Fn EDA accumulation in lesional skin, it remains to be determined whether it is Fn EDA or other endogenous TLR4 ligands that are primarily responsible for maintaining the activated fibroblast phenotype in scleroderma lesions. Indeed, several such damage-associated endogenous TLR4 ligands have been shown to be elevated in scleroderma, including hyaluronan and biglycan. In addition, although the present results clearly implicate the Fn EDA -TLR4 axis in cutaneous fibrosis induced by bleomycin or TGF-b, it will be of great interest to explore the pathogenetic role of the Fn EDA -TLR4 axis in other forms of cutaneous and extracutaneous organ fibrosis. On the basis of our in vitro and in vivo observations, we propose a model for persistent cutaneous fibrosis (Fig. 5) , where activated fibroblasts exposed to extracellular Fn EDA within the fibrotic milieu acquire EDA versus anti-EDA-treated, Sidak's multiple comparison test. ns, not significant. (C to E) Human skin fibroblasts (C and D) or skin fibroblasts (E) from TLR4-mutant and WT mouse were incubated in medium with Fn EDA (10 mg/ml) in the presence or absence of CLI-095 for 72 hours. (C) Left panels: Whole-cell lysates were subjected to Western analysis. Numbers below indicate relative band intensities corrected for tubulin (means from three independent experiments). Right panels: Fibroblasts were immunostained with antibodies to aSMA. Representative immunofluorescence confocal images. Scale bar, 50 mm. Numbers represent fluorescence intensity determined in four randomly selected locations per hpf for each sample (means from three independent experiments). (D) Human skin fibroblasts were transfected with TLR4-specific siRNA or scrambled (Scr) siRNA, followed by incubation in medium with Fn EDA for 72 hours. Left upper panels: mRNA levels were determined by real-time qPCR. Results, normalized with GAPDH mRNA, are means ± SD of triplicate determinations from an experiment representative of two independent experiments. Left lower panels: Immunofluorescence using antibodies to aSMA (red). Representative images. Scale bar, 50 mm. Right panels: Whole-cell lysates were examined by Western analysis. Representative immunoblots. (E) Skin fibroblasts from WT and TLR4-mutant mice in parallel were incubated in medium with Fn EDA for 72 hours. Whole-cell lysates were examined by Western analysis. Representative immunoblots. Numbers below indicate relative band intensities corrected for tubulin (means from two independent experiments). a TLR4-dependent fibrotic phenotype with further stimulation of the production and deposition of ECM molecules including Fn EDA , thereby exacerbating and sustaining fibrogenesis. In this way, fibroblast innate immune signaling triggered by DAMPs might represent one of the cellular pathways responsible for converting self-limited regenerative repair into an intractable fibrotic process. Accordingly, we propose that disrupting sustained TLR4 signaling in the skin lesion represents a potential strategy for breaking the vicious cycle of fibrosis in scleroderma.
MATERIALS AND METHODS
Study design
This was an observational study designed to identify differences among scleroderma patients and healthy controls. Serum levels of Fn EDA were determined in 48 scleroderma patients evaluated at a single center and 16 healthy controls in parallel. All patients met American College of Rheumatology criteria for the classification of systemic sclerosis (SSc) (66) and were subclassified as limited or diffuse cutaneous disease using published criteria (67) . Duration of disease was defined as the interval from the onset of the first non-Raynaud disease manifestation to the time of the serum collection, and patients were subdivided into early (<24 months) and late (>24 months) subgroups. Pulmonary function testing was performed within 6 months of the time of serum collection (68). To assess Fn EDA accumulation in lesional tissue, skin biopsies from the clinically involved forearm of 13 SSc patients and 7 healthy controls were processed in parallel for immunofluorescence. RNA was isolated from skin biopsies of 19 scleroderma patients and 9 healthy controls and processed for real-time qPCR.
Animal experiments were performed according to institutionally approved protocols and in compliance with the guidelines of the Northwestern University Animal Care and Use Committee. In selected experiments, mice were randomly assigned to treatment groups, and treatment groups were blinded during experimental procedures and raw data analysis. No animals or potential outliers were excluded from the data sets presented in this study. All in vitro studies were performed in replicates (n = 3, unless otherwise specified).
Cell culture and reagents Primary human fibroblast cultures were established by explantations from neonatal foreskin or from skin biopsies of the clinically affected forearms of patients with scleroderma and the forearm of healthy adult volunteers (15) . Biopsies were performed with written informed consent and in accordance with protocols approved by the Institutional Review Board for Human Studies at Northwestern University. Primary fibroblasts at low passage grown in monolayers in plastic dishes were studied at early confluence or were embedded into "dermal" collagen plugs used to create 3D organotypic human skin equivalents (15, 69, 70) . Skin fibroblast cultures were also established from 8-week-old C3H/HeJ (TLR4-mutant) and C3H/HeOuJ (wild-type) mice (The Jackson Laboratory) and studied in parallel. Cultures were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (Gibco BRL), 1% vitamin solutions, and 2 mM L-glutamine. All other tissue culture reagents were from Lonza. Cultures were placed in serum-free medium containing 0.1% bovine serum albumin (BSA) for 24 hours before addition of TGF-b (PeproTech) or Fn EDA . To generate Fn EDA , conditioned media were collected from human embryonic IMR90 fibroblasts incubated for 48 hours and purified with affinity chromatography (24) . The purity of Fn EDA was confirmed by Coomassie staining and by Western analysis ( fig. S3A, left panel) ). Endotoxin was quantitated in the Fn EDA preparations with Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher Scientific). In selected experiments, cultures were incubated in medium with Fn EDA preparations that had been subjected to endotoxin removal with Pierce High Capacity Endotoxin Removal Resin (Thermo Fisher Scientific). The TLR4 inhibitor CLI-095 (InvivoGen) or neutralizing antibodies specific for the EDA domain (IST9, Abcam) were added to the cultures 60 min before Fn EDA . Levels of IL-6 secreted in the medium were determined by ELISA (R&D Systems).
Fn
EDA effects in 3D organotypic human skin equivalents To evaluate the effects of Fn EDA in 3D organotypic human skin equivalents, foreskin fibroblasts (300,000 cells/ml) were resuspended in rat tail type I collagen (4 mg/ml, from BD Biosciences) with or without Fn EDA (10 mg/ml) and seeded in 12-well plates (69) . Briefly, foreskin fibroblasts (300,000 cells/ml) were resuspended in a buffered solution of rat tail type I collagen (4 mg/ml, from BD Biosciences) with or without Fn EDA (10 mg/ml) and seeded in 12-well cell culture plates (1.5 ml per well). The dermal collagen plugs were allowed to polymerize for 30 min and then supplemented with 10% DMEM overnight. Primary human epidermal keratinocytes (200,000 cells/ml) isolated from a pool (n = 3) of neonatal foreskins were seeded on top of the dermal collagen plug in E medium [3:1 of DMEM/Ham's F-12 containing 180 mM adenine, insulin (5 mg/ml), transferrin (5 mg/ml), T3 (5 mg/ml), hydrocortisone (0.4 ng/ml), and cholera toxin (10 mg/ml)] supplemented with epidermal growth factor (5 ng/ml) as previously described (70) . After 48 hours of incubation, the skin equivalents were transferred to the top of a metal grid raised above the surface of a 60-mm tissue culture dish and exposed to air to promote epidermal stratification. Culture media were replaced every other day for up to 12 days, and rafts were harvested and lysed for Western analysis, fixed in 10% neutral buffered formalin, and embedded in paraffin for staining or processed for determination of stiffness. Picrosirius Red staining was used to evaluate collagen deposition and fiber alignment in the dermal compartment.
To determine the effect of Fn EDA on substrate stiffness in organotypic raft cultures, a parallel-plate rheometer (Oscillatory Shear Paar Physica MCR Rheometer, Anton Paar GmbH) was used. Circular samples (20-mm diameter) of control and Fn EDA -containing rafts were placed between parallel plates, and plate distance of 0.2 mm was preset to compress the raft. Frequency (F = 0.1 to 10 Hz) sweep tests under oscillatory conditions were conducted at a constant temperature of 37°C, with controlled shear deformation g = 0.5% and 15 measuring points, which led to an average test duration of 16 min. Results, expressed as Young's modulus, were calculated with US-200 software (Anton Paar Co.).
In vitro cell migration and collagen gel contraction assays The effects of Fn EDA on modulating fibroblast function were further evaluated by in vitro wound healing and collagen gel contraction assays (36) . Briefly, human skin fibroblasts were seeded on Fn EDA -coated plates, and confluent monolayers in serum-free DMEM were mechanically wounded with standard p1000 pipette tips. Cultures were monitored for up to 48 hours by phase-contrast microscopy, and pictures were taken at ×25 magnification. The wound gap width (micrometers) was determined at six randomly selected sites per slide at indicated intervals. Collagen gel contraction assays were performed with fibroblasts seeded in type I collagen gels as described (36) . After incubation of the gels in medium containing Fn EDA (10 mg/ml) for the indicated intervals, gel diameters were determined with ImageJ software [National Institutes of Health (NIH), Bethesda, MD]. All experiments were performed in triplicate.
Isolation and analysis of RNA and microRNA At the end of the experiments, total RNA was isolated from explanted fibroblasts, skin biopsies, or organotypic skin rafts and reverse-transcribed to complementary DNA (cDNA) with SuperMix as described (cDNA Synthesis SuperMix, Quanta BioSciences) (15) . The products (50 ng) were amplified with SYBR Green PCR Master Mix (Applied Biosystems) on an Applied Biosystems 7500 Prism Sequence Detection System. The sequence of the primers is shown in Table 1 . MicroRNA was isolated from confluent fibroblasts with the mirVana miRNA Isolation Kit (Ambion/Applied Biosystems) and amplified with TaqMan probes (Applied Biosystems). Levels of miRNA were determined by qPCR with Applied Biosystems 7500 Prism Sequence Detection System (15) . Data were normalized to GAPDH RNA, and fold change in samples was calculated as 2
}.
Western and immunoprecipitation/immunoblot analysis
At the end of the experiments, fibroblasts were harvested, whole-cell lysates were prepared, and equal amounts of proteins (20 to 50 mg per lane) were subjected to Western analysis with primary antibodies specific for type I collagen (Southern Biotechnology), Fn EDA (Sigma-Aldrich), and tubulin (Sigma-Aldrich) as described (15) . Membranes were then incubated with appropriate secondary antibodies and subjected to enhanced chemiluminescence detection with ECL Reagent (Pierce). In other experiments, whole-cell lysates (~600 mg) were immunoprecipitated and subjected to immunoblot analysis with antibodies to Fn EDA (Sigma-Aldrich) and TLR4 (Santa Cruz Biotechnology). Band intensities were quantitated with ImageJ software and corrected for tubulin in each lane.
Transient transfection assays
Subconfluent skin fibroblasts in serum-free medium were transfected with NF-kB-luc with SuperFect reagent (Qiagen), followed by incubation in medium containing Fn EDA (10 mg/ml) in the presence or absence of neutralizing EDA domain-specific antibodies (IST9) and polymyxin B for 24 hours. Cultures were harvested, and whole-cell lysates were assayed for their luciferase activities. In each experiment, fibroblasts were cotransfected with Renilla luciferase pRL-TK plasmids (Promega) as controls for transfection efficiency. Experiments were performed in triplicate and repeated at least twice with consistent results.
Immunofluorescence confocal microscopy To assess the modulation of fibroblast responses by Fn EDA by immunocytochemistry, fibroblasts on eight-well Lab-Tek II chamber glass slides (Nalgene Nunc International) were incubated in serum-free DMEM supplemented with 0.1% BSA containing Fn EDA (10 mg/ml) for up to 72 hours. In selected experiments, fibroblasts were transfected with TLR4-specific siRNA or scrambled control siRNA (Dharmacon) for 24 hours before the addition of Fn-EDA. Cells were then fixed, permeabilized, and incubated with antibodies to type I collagen or aSMA (Sigma) at 1:100 or 1:500 dilution, followed by Alexa Fluorlabeled secondary antibodies (Invitrogen). Nuclei were identified with DAPI. Subcellular distribution of immunofluorescence was evaluated under an immunofluorescence microscope or Zeiss UV Meta 510 confocal microscope (Carl Zeiss Inc.) (15) .
Serum Fn
EDA determinations by ELISAs To determine serum levels of Fn EDA , we developed a specific ELISA. Briefly, 96-well plates were coated with primary antibody to Fn EDA (3E2, Sigma) (1.4 mg/ml in 0.05 M carbonate-bicarbonate buffer, pH 9.6) for 60 min at 37°C followed by blocking with 5% BSA. Serum samples in triplicate were incubated with peroxidase-conjugated goat anti-human fibronectin IgG (1:8000; MP Biomedicals, LLC; catalog no. 55240) for 30 min and washed four times with PBS. Substrate solution (50 ml) was added, and after sufficient color development, reactions were terminated with 0.5 M sulfuric acid and absorbance at 490 nm was measured with an automated plate reader. The sample concentrations were interpolated from standard curves prepared with serial dilutions of known Fn EDA concentrations (detection range, 0.8 to 50.0 mg/ml). To ensure specificity, all assays were run with plasma fibronectin as a negative control.
Fn
EDA expression in scleroderma skin biopsies Paraffin-embedded sections (4 mm) were incubated with primary antibodies against Fn EDA (Sigma, 1:50), followed by mouse Alexa Fluor secondary antibodies (Invitrogen) or DAPI. Slides were mounted, and immunofluorescence was evaluated under a Zeiss UV Meta 510 confocal microscope. Immunopositivity was specific for Fn EDA because substitution of the primary antibody resulted in the absence of staining and Western blot using the antibody showed a single band. Computergenerated 3D image plots of fluorescence intensity were analyzed with ImageJ software (NIH).
Experimental animal models of cutaneous fibrosis
To evaluate the role of Fn EDA in fibrogenesis, we studied cutaneous fibrosis induced by bleomycin or by AdTGF-b1 in Fn EDA -null mice (21) . Eight-week-old female Fn EDA -null mice and wild-type C57BL/6J mice (The Jackson Laboratory) in parallel were given daily subcutaneous injections of bleomycin (10 mg/kg per day) or PBS for 10 days (15) . In other experiments, Fn EDA -null mice and wild-type mice in parallel received two subcutaneous injections of AdTGF-b1 (1 × 10 9 plaque-forming units) or empty vector administered 14 days apart. Mice were sacrificed at day 28, and lesional skin was harvested for analysis. Four-micrometer-thick sections of paraffin-embedded tissues were stained with hematoxylin and eosin, or Masson's trichrome for visualizing collagen. Collagen deposition in the dermis was assessed in Masson's trichrome-stained slides by quantitating blue pixels with ImageJ software. Immunofluorescence analyses were performed by incubating tissues with primary rabbit antibodies against aSMA (Sigma, 1:500), Fn EDA (Abcam, 1:50), or phospho-Smad2 (Cell Signaling Technology, 1:100) followed by Alexa Fluor-labeled rabbit secondary antibodies. Nuclei were detected with DAPI. Slides were mounted, and immunofluorescence was evaluated under a Zeiss UV Meta 510 confocal microscope. Each experimental group consisted of at least five mice. Elastic fibers in the skin were visualized with Verhoeff's stain followed by Van Gieson's counterstain (71) . Accumulation of elastic fibers was quantitated by determining the percentage of positive pixels (elastin stained) from five randomly selected hpf per slide with Adobe Photoshop CS5 (Adobe Systems) (71) .
To investigate the preventive and therapeutic effects of pharmacological TLR4 blockade on cutaneous fibrosis in vivo, C57BL/6J mice were given daily subcutaneous injections of bleomycin (10 mg/kg) or PBS for 15 days. One group of mice was given CLI-095 (2 mg/kg) (InvivoGen) by daily intraperitoneal injections starting concurrently with PBS or bleomycin, and sacrificed on day 24, whereas in another group of mice, daily CLI-095 injections were started at day 15 and mice were sacrificed on day 28. Each experimental group consisted of five mice.
Statistical analysis
Data are presented as means ± SD. Two-tailed Student's t test or MannWhitney U test was used for comparisons between two groups, and P < 0.05 was considered significant. Spearman's rank correlation coefficient was used to analyze the relationship between serum Fn EDA levels and clinical parameters. Comparisons among three or more groups were performed with ANOVA followed by Bonferroni correction or Sidak's multiple comparison test. Data were analyzed with GraphPad Prism (version 5 or 6; GraphPad Software).
Study approval
Animal studies were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the Northwestern University. Studies involving human subjects were approved by the Institutional Review Board of the Northwestern University, and all the participants provided written informed consent.
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